REVB vs RLMD

Revelation Biosciences, Inc. vs Relmada Therapeutics, Inc. — Valuation Comparison 2026

REVB

Biotechnology
Revelation Biosciences, Inc.
Quality
4.1
out of 10
Value Trap
33
LOW
Price
$1.10
Last close
Models
7/13
Active
VS

RLMD

Biotechnology
Relmada Therapeutics, Inc.
Quality
4.4
out of 10
Value Trap
24
SAFE
Price
$7.25
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType REVB Fair ValueREVB Upside RLMD Fair ValueRLMD Upside
Bayesian DCF Intrinsic $2.20 +99.8% $1.99 -72.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $5.68 +416.4% $1.53 -78.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for REVB vs RLMD — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

REVB vs RLMD — Which Stock Is More Undervalued?

RLMD scores higher with a 4.4/10 quality rating vs REVB's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Revelation Biosciences, Inc. (REVB) and Relmada Therapeutics, Inc. (RLMD) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

REVB currently trades at $1.10 with a QOC of 4.1/10, while RLMD trades at $7.25 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).